A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Neoadjuvant Pembrolizumab and IO102-103 for Squamous Cell Carcinoma of the Head and Neck (SCCHN).
- Status
- RECRUITING
- Phase
- PHASE2
Lenvatinib, Pembrolizumab, and Tumor Treating Fields (TTFields) for Second-line Treatment of Glioblastoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus
- Status
- RECRUITING
- Phase
- PHASE2
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Propranolol and Pembrolizumab in Advanced Soft Tissue Sarcoma Patients
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
- Status
- RECRUITING
- Phase
- PHASE2
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembro Plus CAR T-cell Therapy in R/R in PMBCL
- Status
- RECRUITING
- Phase
- PHASE2
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma
- Status
- TERMINATED
- Phase
- PHASE2
Pembrolizumab in Locally Advanced Sinonasal Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
PET Adapted Brentuximab Vedotin and Pembrolizumab in Combination With Doxorubicin and Dacarbazine in Classic Hodgkin Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Status
- RECRUITING
- Phase
- PHASE3
Predictive Biomarkers of Response to Checkpoint Inhibitors in Triple Negative Breast Cancer: a Multiomics Platform
- Status
- RECRUITING
- Phase
- N/A
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
- Status
- RECRUITING
- Phase
- PHASE2